Pharmaceutical Technology

JULY 4, 2022

GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. It could potentially support expanding the specialty medicines business of GSK on obtaining approval. The launch of momelotinib in the US is scheduled for next year.

Vaccines 122

Vaccines 122

Pharmacy Is Right For Me

JANUARY 25, 2023

I worked most of my career in the biopharmaceutical industry in various commercial roles, such as sales, marketing account management, strategic consulting, and business development. I started with GlaxoSmithKline in North Carolina and went with them to New York City after that. Lastly, get as much diverse experience as you can.

Community Pharmacies 130

Community Pharmacies Insurance Patient Care 130

pharmaphorum

APRIL 29, 2021

GlaxoSmithKline’s CEO Emma Walmsley said the company is focused on pursuing its strategy to spin off its consumer business after downbeat set of first quarter results. But Walmsley’s upbeat message about the plans to split off the company’s consumer business seem to have done the trick with investors.

Vaccines 72

Vaccines FDA 72

pharmaphorum

JUNE 3, 2021

In the newly-created role, Goldstein will oversee the execution of 4,500 projects per year across The Bloc’s US client business. Clients include Johnson & Johnson, Oreo, Coca-Cola, Novartis, Diageo, eBay, GlaxoSmithKline, Time Warner, and Marvel. In 2021, the agency celebrated 21 years of business.

52

52

pharmaphorum

FEBRUARY 23, 2022

GlaxoSmithKline’s consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. GSK holds a majority controlling interest of 68% in the JV, with and Pfizer holding the remaining 32%. billion.

Vaccines 52

Vaccines 52

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. “Investors won’t appreciate the overhang,” he added. mRNA ambitions.

Vaccines 100

Vaccines 100

pharmaphorum

NOVEMBER 14, 2021

After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations. Gorsky said that the decision is the “best way to…drive profitable growth” for all J&J’s business units.

59

59

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. billion, but still came in ahead of analyst expectations.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

DECEMBER 22, 2022

Our programme is designed to highlight excellence within the sector by looking at a range of corporate activities including deals, business projects and company initiatives, both internal and in the community. Business Expansion. Innovation. The category includes any projects that demonstrate an innovative approach to the market.

FDA 52

FDA Insurance Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MAY 21, 2021

GlaxoSmithKline has sold its entire stake in its respiratory partner Innoviva, raising $392 million and simplifying its business ahead of a split into two. GSK is pushing ahead with a split into an innovative drugs business and a consumer healthcare firm, while the spectre of activist investor Elliott Management hangs over it.

59

59

pharmaphorum

OCTOBER 13, 2022

He specialises in working with clients to develop innovative solutions as they evolve to meet the needs of a changing healthcare and business landscape. His work with clients focused on creating internal and external innovation platforms to deliver business value. He holds a Masters of Business Administration from the Leonard N.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

DECEMBER 19, 2022

Business Expansion. Business Expansion is one of our largest categories and looks at the core functions of business operations within the sector. What all the ranked entities have in common is the demonstration of new concepts not just within their own business but in the sector as a whole. Investments. Product Launches.

52

52

pharmaphorum

NOVEMBER 13, 2020

Since Covid-19 hit, many industries have shifted a heavier weighting of their business into the online world, relying on e-commerce and digital engagement to counterbalance the reduced ability for physical interactions. And for those pharma businesses that can get it right, digital adoption is certainly the way forward.

Pharmaceutical Companies 124

Pharmaceutical Companies Pharmaceutical Companies 124

Viseven

OCTOBER 3, 2023

Viseven and Veeva have been partners for many years, providing advanced technology and content expertise to pharma and life sciences businesses and agencies of all sizes, and it was a big honor and privilege for the Viseven team to be at the event and make its own contribution to the evolution of biopharma digital marketing.

52

52

pharmaphorum

MAY 12, 2022

J&J announced its intention to separate consumer health from its faster-growing prescription medicine and medical device businesses last November, creating a separate company that will be home to well-recognised brands, including Band-Aid dressings, Johnson’s baby range, Listerine mouthwash, and Tylenol painkillers.

52

52

pharmaphorum

NOVEMBER 22, 2021

Veritas and Elliott were reportedly seeking a deal worth around $20 billion, and the WSJ says that the current offer also includes the assumption of Athenahealth’s debt, which has risen since the private equity groups took charge of the business.

64

64

pharmaphorum

JULY 2, 2021

GlaxoSmithKline’s board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands firmly behind the leadership of chief executive Emma Walmsley. billion pipeline-boosting alliance with immunology specialist Alector.

Communication 52

Communication 52

pharmaphorum

AUGUST 24, 2020

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs. The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3

80

80

pharmaphorum

FEBRUARY 26, 2021

Tribal Health’s clients include GlaxoSmithKline, Gilead and Medela. I’m looking forward to working with our clients to help them deliver meaningful change to their customers and business.”. Prior to Publicis Health, Rizwani worked in strategy and innovation projects at DigitasLBi and Blue Latitude.

52

52

pharmaphorum

NOVEMBER 23, 2021

Less well known is that Baidu has become a major player in AI, with a business based in Silicon Valley that like Google is working on a host of projects including personal assistants driven by machine learning, autonomous cars and healthcare. Specific financial terms have not been disclosed.

Vaccines 105

Vaccines Immunization 105

pharmaphorum

NOVEMBER 19, 2020

Trans-Atlantic biotech venture capital firm SR One has completed its spin-out from GlaxoSmithKline and closed its first fund with $500m in its coffers. It’s been a busy time for life sciences VC, with the likes of Canaan Partners, Atlas Venture creating new funds amid the investment boom in life sciences amid the COVID-19 pandemic.

59

59

pharmaphorum

JULY 1, 2021

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect criticism of her leadership from activist investor Elliott Management – but finds herself in the firing line once again today.

Vaccines 52

Vaccines 52

pharmaphorum

APRIL 16, 2021

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn around the company’s fortunes. Elliott was founded in 1977 by Paul Singer and its European business is run by his son, Gordon.

Packaging 69

Packaging Chemotherapy Vaccines 69

pharmaphorum

NOVEMBER 6, 2020

Lilly is one of a select but growing group of pharma companies – along with Pfizer, Bayer, GlaxoSmithKline, Novartis, Merck & Co, Sanofi and others – who have made CIDO/CDO appointments in the last few years. Aarti has been an invaluable member of our executive committee,” said Lilly’s chairman and CEO David Ricks.

56

56

pharmaphorum

OCTOBER 27, 2021

GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on Xevudy for mild-to-moderate disease. That helped offset a 12% decline for Seretide/Advair (salmeterol/fluticasone propionate) to £324 million due to generic competition.

Vaccines 59

Vaccines 59

pharmaphorum

DECEMBER 9, 2020

A pioneer in digital engagement, Razorfish Health builds brands that thrive at the forefront of the evolving practice of modern medicine with a focus on inventive, data-driven communications to deliver ever-better business and health outcomes.

Communication 52

Communication 52

ISPE

JULY 7, 2023

she provides support to overcome the business and regulatory challenges to patient safety, product quality, and data integrity within the life sciences industry. GlaxoSmithKline (GSK) was a constant in Heather Watson’s life. “I I was in America on business in February 2020. As Company Director of TenTenTen Consulting Ltd.,

Communication 52

Communication 52

pharmaphorum

OCTOBER 1, 2021

GlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed clinical trials. It also comes as the UK-based pharma group is fending off criticism of its top leadership – including chief executive Emma Walmsley – from activist investors. billion.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

MAY 25, 2021

Also in the spotlight is teclistamab, which targets CD3 and BCMA, a myeloma target that already features in approved therapies, notably GlaxoSmithKline’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) and Bristol-Myers Squibb/bluebird bio’s Abecma CAR-T therapy (idecabtagene vicleucel).

FDA 101

FDA 101

pharmaphorum

MAY 26, 2021

The acquisition of one of the UK’s biggest biotech companies comes as Vectura is in the midst of a business restructuring that has seen it pivot away from developing its own respiratory therapies and towards an outsourcing model in which it provides contract development and manufacturing services to other biopharma companies.

Compounding 64

Compounding 64

pharmaphorum

DECEMBER 16, 2022

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Reagents supplier The Native Antigen Company has hired a new business development manager, Richard White , and senior product manager, Pardeep Sharda.

52

52

pharmaphorum

SEPTEMBER 15, 2021

Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of its workforce. Following after are wholly-owned lung-selective JAK inhibitors nezulcitinib (TD-0903) and TD-8236 which are in phase 2 trials for inflammatory lung diseases.

Labelling 52

Labelling 52

pharmaphorum

MARCH 1, 2022

He specialises in bringing digital B2B and B2Cproducts to market and has experience in business strategy and operations, sales and marketing and proposition design and development. Sheena Gomez is a local delivery lead manager for GlaxoSmithKline (GSK). He holds a First Class Honours BSc in Economics from UCL.

Vaccines 96

Vaccines Hospitals 96

pharmaphorum

MAY 18, 2021

Speculation is mounting GlaxoSmithKline’s CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in the struggling pharma.

Vaccines 59

Vaccines 59

pharmaphorum

MARCH 26, 2021

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment. He also apologised in the statement to the female GSK employee whose sexual harassment complaint resulted in him being fired from GSK’s Galvani Bioelectronics unit.

Vaccines 52

Vaccines 52

pharmaphorum

MAY 20, 2021

The Oxford, UK-based company has also signed pharma partnerships with Bayer , Sanofi, GlaxoSmithKline , and Roche, as well as co-development deals with smaller biotechs including Evotec, Blue Oak Pharma, Apeiron and Rallybio, but the latest with BMS is its largest to date.

69

69

pharmaphorum

DECEMBER 22, 2020

GlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack as chief scientific officer Hal Barron pursues a strategy to develop “transformational medicines”. This deal involves an upfront payment of $7 million but there is up to $154.5

Immunization 52

Immunization 52